Nippon Paint Holdings GAAP EPS of ¥45.30, revenue of ¥1023.68B; updates FY 2026 outlook
Nippon Paint Holdings Co., Ltd. press release (NPCPF): 1H GAAP EPS of ¥45.30. Revenue of ¥1,023.68B (+20.1% Y/Y).
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
Nippon Paint Holdings Co., Ltd. press release (NPCPF): 1H GAAP EPS of ¥45.30. Revenue of ¥1,023.68B (+20.1% Y/Y).
Nippon Paint Holdings GAAP EPS of ¥45.30, revenue of ¥1023.68B; updates FY 2026 outlook | Seeking Alpha
Nippon Paint Holdings Co., Ltd.
press release
(
NPCPF
): 1H GAAP EPS of ¥45.30.
Revenue of Â¥1,023.68B (+20.1% Y/Y).Â
More on Nippon Paint Holdings Co., Ltd.
Nippon Paint Holdings Co., Ltd. 2026 Q2 - Results - Earnings Call Presentation
Nippon Paint Holdings Co., Ltd. (NPPHY) Q1 2026 Earnings Call Transcript
Nippon Paint Holdings Co., Ltd. 2026 Q1 - Results - Earnings Call Presentation
Nippon Paint has made multiple offers for Akzo Nobelâs decorative paints unit - Bloomberg
Sherwin-Williams, Nippon Paint abandon pursuit of AkzoNobel after rejected bids
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
Pulse Biosciences targets early October enrollment completion for 164-patient NANOPULSE-AF study (NASDAQ:PLSE)
Pulse Biosciences (PLSE) Q2 2026 earnings call: fast NANOPULSE-AF enrollment to early Oct, CE Mark timeline, revenue & cash runway.
Denali expects $10M-$12M in Q3 AVLAYAH net product revenue as launch momentum builds (NASDAQ:DNLI)
Denali Therapeutics (DNLI) Q2 2026 earnings call highlights: AVLAYAH launch ramp, Q3 revenue guide $10â$12M, $1.1B cash, pipeline updatesâread now.
Expensify outlines $12M to $14M in 2026 free cash flow guidance backed by share repurchases (NASDAQ:EXFY)
Expensify (EXFY) Q2 2026 earnings call recap: revenue, FCF guidance raised to $12â$14M, New vs Classic growth, AI and buybacks.
Lineage outlines cash runway into Q3 2028 while targeting COR1 in vivo data by year-end (NYSE:LCTX)
Lineage Cell Therapeutics (LCTX) Q2 2026 earnings call: OpRegen, AlloSCOPE/Lineage 3.0 pipeline, cash runway to Q3 2028 & catalystsâread now.